Sulfadoxine-Pyrimethamine–Based Combinations for Malaria: A Randomised Blinded Trial to Compare Efficacy, Safety and Selection of Resistance in Malawi
Open Access
- 13 February 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (2) , e1578
Abstract
In Malawi, there has been a return of Plasmodium falciparum sensitivity to chloroquine (CQ) since sulfadoxine-pyrimethamine (SP) replaced CQ as first line treatment for uncomplicated malaria. When used for prophylaxis, Amodiaquine (AQ) was associated with agranulocytosis but is considered safe for treatment and is increasingly being used in Africa. Here we compare the efficacy, safety and selection of resistance using SP or CQ+SP or artesunate (ART)+SP or AQ+SP for the treatment of uncomplicated falciparum malaria. 455 children aged 1–5 years were recruited into a double-blinded randomised trial comparing SP to the three combination therapies. Using intention to treat analysis with missing outcomes treated as successes, and without adjustment to distinguish recrudescence from new infections, the day 28 adequate clinical and parasitological response (ACPR) rate for SP was 25%, inferior to each of the three combination therapies (p3 cells/µl by day 14, more commonly after AQ+SP (p = 0.03). The mutation pfcrt 76T, associated with CQ resistance, was detected in none of the pre-treatment or post-treatment parasites. The prevalence of the pfmdr1 86Y mutation was higher after treatment with AQ+SP than after SP, p = 0.002. The combination AQ+SP was highly efficacious, despite the low efficacy of SP alone; however, we found evidence that AQ may exert selective pressure for resistance associated mutations many weeks after treatment. This study confirms the return of CQ sensitivity in Malawi and importantly, shows no evidence of the re-emergence of pfcrt 76T after treatment with CQ or AQ. Given the safety record of AQ when used as a prophylaxis, our observations of marked falls in neutrophil counts in the AQ+SP group requires further scrutiny. Controlled-Trials.com ISRCTN22075368Keywords
This publication has 31 references indexed in Scilit:
- Resistance-Mediating Plasmodium falciparum pfcrt and pfmdr1 Alleles after Treatment with Artesunate-Amodiaquine in UgandaAntimicrobial Agents and Chemotherapy, 2007
- Sustained clinical efficacy of sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Malawi after 10 years as first line treatment: five year prospective studyBMJ, 2004
- Reemergence of Chloroquine‐SensitivePlasmodium falciparumMalaria after Cessation of Chloroquine Use in MalawiThe Journal of Infectious Diseases, 2003
- EFFICACY OF AMODIAQUINE ALONE AND COMBINED WITH SULFADOXINE-PYRIMETHAMINE AND OF SULFADOXINE PYRIMETHAMINE COMBINED WITH ARTESUNATEThe American Journal of Tropical Medicine and Hygiene, 2003
- Amodiaquine for treating malariaCochrane Database of Systematic Reviews, 2003
- COMPARATIVE EFFICACY OF AMINOQUINOLINE-ANTIFOLATE COMBINATIONS FOR THE TREATMENT OF UNCOMPLICATED FALCIPARUM MALARIA IN KAMPALA, UGANDAThe American Journal of Tropical Medicine and Hygiene, 2003
- DISTINGUISHING RECRUDESCENCE FROM REINFECTION IN A LONGITUDINAL ANTIMALARIAL DRUG EFFICACY STUDY: COMPARISON OF RESULTS BASED ON GENOTYPING OF MSP-1, MSP-2, AND GLURPThe American Journal of Tropical Medicine and Hygiene, 2003
- Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trialThe Lancet, 2002
- Molecular Markers for Failure of Sulfadoxine‐Pyrimethamine and Chlorproguanil‐Dapsone Treatment ofPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 2002
- Amodiaquine remains effective for treating uncomplicated malaria in West and Central AfricaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1999